BRAFV600E-Driven Lung Tumorigenesis Requires Ligand-Mediated Activation of ERBB Receptor Signaling
Mélanie A. Dacheux, Mengting Wu, Michael T. Scherzer, Monique Nillson, Brandon Murphy, Sophia S. Schuman, Zhenlin Ju, Trever Grant Bivona, Piro Lito, Matthew Gumbleton, Sonam Puri, Wallace Akerley, Jing Wang, Kaiwen Wang, John Victor Heymach, , Aria Vaishnavi
This study shows that BRAFV600E-driven lung cancer requires ERBB receptor signaling via ligand-mediated activation, and combined inhibition of BRAFV600E and ERBB improves therapeutic outcomes.
bioRxiv · May 4, 2025 · PreprintCancer Biology